青岛海尔生物医疗股份有限公司 关于公司 2025 年度"提质增效重回报"专项行动方案的 青岛海尔生物医疗股份有限公司（以下简称"公司"、"海尔生物"）为践行 "以投资者为本"的上市公司发展理念，维护公司全体股东利益，增强投资者信 心，促进公司长远健康可持续发展，基于对公司未来发展前景的信心和对公司价 值的认可，已连续两年发布"提质增效重回报"专项行动方案。根据 2025 年 3 月 29 日发布的《海尔生物"提质增效重回报"2024 年度评估报告暨 2025 年度 行动方案》，报告期内公司积极开展和落实各项工作，现将 2025 年上半年的主要 工作成果报告如下： 一、 加快发展新质生产力，聚焦四大产业，夯实全球市场竞争力 在人工智能底座深度融合的基础上，报告期内四横四纵平台加强联动，驱 动研发效率提升、技术成果产出加快和产品创新提速。上半年公司研发投入 1.60 亿元，占营业收入的比重为 13.39%；公司新品研发周期同比缩短 6%，发明专利 累计获得数同比增长 48%，累计 32 项成果被鉴定为国际领先水平成果，牵头或 参与起草国家/行业/地方团体等标准 64 项，获得省级以上科技奖励 45 项，上半 年荣 ...

海尔生物公告，2025年上半年营业收入11.96亿元，同比下降2.27%。归属于上市公司股东的净利润1.43 亿元，同比下降39.09%。基本每股收益0.45元／股，同比减少39.19%。 ...

Core Viewpoint - Haier Biomedical is a service provider for life sciences and medical innovation digital solutions, focusing on low-temperature storage, laboratory solutions, smart medication, and blood technology, with products covering over 150 countries and regions [1] Group 1: Stock Performance - As of August 20, 2025, Haier Biomedical's stock price closed at 34.91 yuan, down 0.09 yuan, a decrease of 0.26% from the previous trading day [1] - The trading volume on that day was 41,111 hands, with a transaction amount of 1.42 billion yuan [1] Group 2: Strategic Partnerships - On August 19, 2025, Haier Biomedical signed a strategic cooperation agreement with Thailand's RAM Medical Group, focusing on pharmacy automation and smart healthcare solutions [1] - RAM Medical Group is the second-largest private hospital group in Thailand, operating 50 hospitals [1] - The agreement includes a pilot project for pharmacy automation solutions, covering outpatient pharmacy automation systems and intelligent inventory management modules [1] Group 3: Financial Updates - Haier Biomedical announced it will hold a semi-annual performance briefing on August 28, 2025 [1] - On August 20, 2025, the net inflow of main funds into Haier Biomedical was 389,900 yuan, with a cumulative net inflow of 1.65 million yuan over the past five days [1]

Core Insights - The collaboration between Haier Biomedical and RAM Medical Group marks a significant step in Haier's overseas strategy, transitioning from "product output" to "ecosystem co-construction" in Southeast Asia [1][4] - Southeast Asia, with its growing elderly population and economic development, presents a lucrative market for medical technology, particularly in Thailand, which has urgent needs for automation and smart medical devices [2][5] Group 1: Strategic Collaboration - Haier Biomedical and RAM Medical Group signed a strategic cooperation agreement focusing on pharmacy automation and smart medical solutions [1][3] - The partnership aims to implement automated pharmacy solutions, enhancing efficiency and safety in drug management for local and global medical tourists [3] Group 2: Market Potential - Southeast Asia's population of 670 million and over 10% elderly growth rate make it a key market for medical upgrades, providing a strategic entry point for Chinese medical technology firms [2] - RAM Medical Group operates 50 hospitals with 7,800 beds, emphasizing the need for automation upgrades that align with Haier Biomedical's technological capabilities [2] Group 3: Customized Solutions - Haier Biomedical's strategy includes tailored solutions for the Southeast Asian market, addressing local climate, medical processes, and regulatory standards [4] - The collaboration will establish a local operational center to facilitate marketing, logistics, and after-sales service, transitioning from product sales to service provision [4] Group 4: Broader Implications - The partnership is seen as a model for Chinese medical technology firms to redefine their value proposition in international markets, moving from cost-based competition to technology-driven solutions [5][6] - As the collaboration progresses, it is expected to enhance Haier Biomedical's market presence in Southeast Asia and potentially replicate this model in other emerging markets [6]

Core Viewpoint - The collaboration between Haier Biomedical and RAM Medical Group marks a significant step in China's medical technology companies' global expansion, focusing on technology innovation and localized services in Southeast Asia [1][3]. Group 1: Strategic Collaboration - Haier Biomedical signed a strategic cooperation agreement with RAM Medical Group, one of Thailand's major private hospital groups, to enhance automation in pharmacies and smart healthcare solutions [1][3]. - The partnership aims to implement pharmacy automation solutions, including outpatient pharmacy automation systems and smart inventory management modules, to improve efficiency and safety in medical services [4][5]. Group 2: Market Potential in Southeast Asia - Southeast Asia, with a population of 670 million and over 10% elderly population growth, is becoming a key market for medical industry expansion [3]. - Thailand, as a regional medical hub, has a pressing need for upgrades in pharmacy automation and smart medical devices, providing a strategic entry point for Chinese medical technology companies [3][4]. Group 3: Customized Solutions and Local Operations - Haier Biomedical focuses on customized solutions tailored to the Southeast Asian market, addressing local climate, medical processes, and policy standards [4][5]. - The company has established localized operational centers covering marketing, logistics, and after-sales services, transitioning from a product-selling model to a service-oriented approach [5][6]. Group 4: Broader Implications for Chinese Medical Technology - The collaboration is seen as a model for the upgrade of the Southeast Asian medical industry, showcasing a shift from cost-based competition to value-driven innovation [6]. - Haier Biomedical's approach emphasizes technology-driven standards and patient experience, positioning Chinese medical technology as a leader rather than a follower in the global market [6].

Core Insights - The collaboration between Haier Biomedical and RAM Medical Group marks a significant step in Haier's "one country, one policy" overseas strategy, focusing on technology solutions and localized services in Southeast Asia [1][5][6] - Southeast Asia, with its growing elderly population and economic development, presents a lucrative market for medical technology, particularly in Thailand, which has urgent needs for automation and smart medical devices [3][5] Group 1: Strategic Collaboration - Haier Biomedical has signed a strategic cooperation agreement with RAM Medical Group to implement pharmacy automation and smart medical solutions, enhancing healthcare efficiency and safety [4][6] - The partnership aims to create a comprehensive ecosystem by integrating customized products and localized operations, transitioning from merely selling products to providing services [5][6] Group 2: Market Potential - Southeast Asia's population of 670 million and over 10% growth in the elderly demographic make it a prime market for medical technology advancements [3][7] - The collaboration is expected to serve not only local Thai patients but also international medical tourists, thereby injecting efficiency and safety into regional healthcare services [4][6] Group 3: Technological Innovation - Haier Biomedical's approach emphasizes "customized technology + localized operations" to address the diverse needs of different medical markets, showcasing its capabilities in low-temperature storage and laboratory solutions [3][5] - The partnership will initially focus on pharmacy automation solutions, including outpatient pharmacy systems and smart inventory management, to streamline the drug distribution process [4][6] Group 4: Future Outlook - The collaboration is seen as a model for replicating successful strategies in other emerging markets, potentially expanding Haier Biomedical's influence in the global healthcare landscape [6][7] - As the partnership develops, RAM Medical Group plans to gradually adopt a full range of Haier Biomedical's products and solutions, indicating a shift from isolated projects to a comprehensive healthcare ecosystem [5][6]

Core Viewpoint - The company, Qingdao Haier Biomedical Co., Ltd., is set to hold a half-year performance briefing on August 28, 2025, to discuss its operational results and financial status for the first half of 2025, allowing investors to engage in a Q&A session [2][3]. Group 1: Meeting Details - The performance briefing will take place on August 28, 2025, from 13:00 to 14:00 [5]. - The meeting will be held at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [4][5]. - Investors can submit questions from August 21 to August 27, 2025, through the Roadshow Center website or via the company's email [6]. Group 2: Participation Information - Investors can participate in the briefing by logging into the Shanghai Stock Exchange Roadshow Center on the scheduled date and time [4][5]. - The company will address commonly asked questions during the briefing, ensuring transparency and engagement with investors [3][6]. - Contact information for the company's securities department is provided for further inquiries [6].

证券日报网讯 8月19日晚间，海尔生物发布公告称，公司将于2025年8月28日召开2025年半年度业绩说 明会。 （文章来源：证券日报） ...

Company Overview - Qingdao Haier Biomedical Co., Ltd. focuses on providing optimal user experiences for life science users, including pharmaceutical and biological enterprises, research institutions, hospitals, and public health organizations [2] - The company has developed two main business segments: life sciences and medical innovation, offering comprehensive digital solutions such as smart laboratories and digital hospitals [2] Product Portfolio - Major products include low-temperature storage boxes, automated biological sample storage systems, fully automated cell culture workstations, and various medical automation products [2] - The company has received multiple awards and certifications, enhancing its innovation capabilities in life sciences and medical fields [2] Financial Performance - For Q1 2025, the company reported revenue of 689 million yuan, a year-on-year increase of 0.30%, and a net profit of 110 million yuan, a decrease of 19.88% [3] - The gross profit margin stands at 48.35% [3] Market Position - As of August 19, the company's stock closed at 35.0 yuan, with a rolling PE ratio of 32.80 times, and a total market capitalization of 11.128 billion yuan [1] - The average PE ratio in the medical device industry is 59.49 times, with a median of 40.19 times, placing the company at the 64th position in the industry ranking [1][3] Institutional Holdings - As of Q1 2025, there is one institutional holder of the company, with a total holding of 430,200 shares valued at 1.3 million yuan [1]

证券代码：688139 证券简称：海尔生物 公告编号：2025-042 青岛海尔生物医疗股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 青岛海尔生物医疗股份有限公司（以下简称"公司"）将于 2025 年 8 月 27 日发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财务状况，公司计划于 2025 年 08 月 28 日（星期四） 13:00-14:00 举行 2025 年半年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年半年度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 会议召开时间：2025 年 08 月 28 日(星期四)下午 13:00-14:00 会议召开地点：上海证券交易所上证 ...